A Role for the internal repeat of the Kaposi's sarcoma-associated herpesvirus latent nuclear antigen in the persistence of an episomal viral genome

Journal of Virology

Volumn 86, Issue 3, 2012, Pages 1883-1887

  Alkharsah, Khaled R ^a,b   Schulz, Thomas F ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b PRINCE MOHAMMAD BIN FAHD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; LATENCY ASSOCIATED NUCLEAR ANTIGEN;

AMINO TERMINAL SEQUENCE; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CARBOXY TERMINAL SEQUENCE; CELL SORTER; CONTROLLED STUDY; EPISOME; GENE DELETION; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; INTERNAL REPEAT; MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; ORF73 GENE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE GENETICS; VIRUS GENE; VIRUS GENOME; WILD TYPE;

ANTIGENS, NUCLEAR; ANTIGENS, VIRAL; GENOME, VIRAL; HERPESVIRUS 8, HUMAN; PLASMIDS;

HUMAN HERPESVIRUS 8;

EID: 84857076241     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06029-11     Document Type: Article

References (22)

1. Ballestas ME, Chatis PA, Kaye KM. 1999. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284:641- 644.
2. Ballestas ME, Kaye KM. 2001. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA. J. Virol. 75:3250 -3258.
3. Barbera AJ, et al. 2006. The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science 311:856-861.
4. Borst EM, Posfai G, Pogoda F, Messerle M. 2004. Mutagenesis of herpesvirus BACs by allele replacement. Methods Mol. Biol. 256:269 -279.
5. Cai X, Cullen BR. 2006. Transcriptional origin of Kaposi's sarcomaassociated herpesvirus microRNAs. J. Virol. 80:2234 -2242.
6. De León Vázquez E, Kaye KM. 2011. The internal Kaposi's sarcomaassociated herpesvirus LANA regions exert a critical role on episome persistence. J. Virol. 85:7622-7633.
7. Dittmer D, et al. 1998. A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J. Virol. 72:8309-8315.
8. Dupin N, et al. 1998. Prevalence of human herpesvirus 8 infection measured by antibodies to a latent nuclear antigen in patients with various dermatologic diseases. Arch. Dermatol. 134:700 -702.
9. Garber AC, Hu J, Renne R. 2002. Latency-associated nuclear antigen (LANA) cooperatively binds to two sites within the terminal repeat, and both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication. J. Biol. Chem. 277:27401-27411.
10. Grundhoff A, Ganem D. 2004. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J. Clin. Invest. 113:124 -136.
11. Krishnan HH, et al. 2004. Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J. Virol. 78:3601-3620.
12. Kwun HJ, et al. 2007. Kaposi's sarcoma-associated herpesvirus latencyassociated nuclear antigen 1 mimics Epstein-Barr virus EBNA1 immune evasion through central repeat domain effects on protein processing. J. Virol. 81:8225- 8235.
13. Lagunoff M, et al. 2002. De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells. J. Virol. 76:2440 -2448.
14. Li H, Komatsu T, Dezube BJ, Kaye KM. 2002. The Kaposi's sarcomaassociated herpesvirus K12 transcript from a primary effusion lymphoma contains complex repeat elements, is spliced, and initiates from a novel promoter. J. Virol. 76:11880 -11888.
15. Lim C, Seo T, Jung J, Choe J. 2004. Identification of a virus trans-acting regulatory element on the latent DNA replication of Kaposi's sarcomaassociated herpesvirus. J. Gen. Virol. 85:843- 855.
16. Muralidhar S, et al. 1998. Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J. Virol. 72:4980-4988.
17. Rainbow L, et al. 1997. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J. Virol. 71:5915-5921.
18. Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y. 2001. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J. Virol. 75:429-438.
19. Russo JJ, et al. 1996. Nucleotide sequence of the Kaposi sarcomaassociated herpesvirus (HHV8). Proc. Natl. Acad. Sci. U. S. A. 93: 14862-14867.
20. Viejo-Borbolla A, et al. 2005. Brd2/RING3 interacts with a chromatinbinding domain in the Kaposi's sarcoma-associated herpesvirus latencyassociated nuclear antigen 1 (LANA-1) that is required for multiple functions of LANA-1. J. Virol. 79:13618 -13629.
21. Zaldumbide A, Ossevoort M, Wiertz EJ, Hoeben RC. 2007. In cis inhibition of antigen processing by the latency-associated nuclear antigen I of Kaposi sarcoma herpes virus. Mol. Immunol. 44:1352-1360.
22. Zhou FC, et al. 2002. Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J. Virol. 76:6185- 6196.